A Phase 2 interventional study of V181 High-Potency Level and V181 Mid-Potency Level in Dengue Disease and Dengue Virus, sponsored by Merck Sharp & Dohme LLC. Completed at 32 sites in 7 countries. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid-Potency Level vaccine. This study will also evaluate the safety and tolerability of 3 different V181 potency level vaccines. The primary hypothesis of the study is that the V181 Low-Potency Level vaccine is non-inferior to the V181 Mid-Potency Level vaccine for each of the 4 dengue serotypes based on GMTs at Day 28 post-vaccination.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
This study's enrollment of 1,271 is above the median of 132 across 197 interventional studies indexed under Dengue.
Browse Dengue studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 0.5mL subcutaneous (SC) dose of V181 High-Potency vaccine.
Biological: V181 High-Potency Level
Participants will receive a single 0.5mL SC dose of V181 Mid-Potency vaccine.
Biological: V181 Mid-Potency Level
Participants will receive a single 0.5mL SC dose of V181 Low-Potency vaccine.
Biological: V181 Low-Potency Level
Participants will receive a single SC 0.5 mL dose of placebo.
Biological: Placebo
0.5 mL SC dose of V181 High-Potency vaccine
0.5 mL SC dose of V181 Mid-Potency vaccine
0.5 mL SC dose of V181 Low-Potency vaccine
0.5 mL SC dose of placebo
Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)
A dengue VRNT was conducted to assess neutralizing antibody Geometric Mean Titers (GMTs) for each of the 4 dengue vaccine serotypes (DENV1, DENV2, DENV3, and DENV4) in specimens collected from participants on Day 28 post-vaccination.
Time frame: Day 28 post-vaccination
Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)
An SAE is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.
Time frame: Up to 28 days post-vaccination
Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs include pain, erythema (redness), and swelling.
Time frame: Up to 5 days post-vaccination
Percentage of Participants With Solicited Systemic AEs
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include rash, headache, fatigue (tiredness), pyrexia (oral temperature ≥100.4 °F or 38.0 °C), myalgia (muscle pain), and arthralgia (joint pain).
Time frame: Up to 28 days post-vaccination
Adult males or females, in generally good health, between 18 to 50 years of age, and without a history of dengue or Zika natural infection or prior receipt of any other dengue vaccine were enrolled in this study.
| Milestone | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo |
|---|---|---|---|---|
| Started | 231 | 463 | 461 | 116 |
| Vaccinated at baseline | 231 | 461 | 459 | 115 |
| Completed | 205 | 430 | 431 | 106 |
| Not completed | 26 | 33 | 30 | 10 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 22 | 20 | 20 | 7 |
| Withdrew: Randomized by mistake without study treatment | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 11 | 7 | 3 |
| Withdrew: Participant left the country | 0 | 0 | 1 | 0 |
A dengue VRNT was conducted to assess neutralizing antibody Geometric Mean Titers (GMTs) for each of the 4 dengue vaccine serotypes (DENV1, DENV2, DENV3, and DENV4) in specimens collected from participants on Day 28 post-vaccination.
| Titer | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo |
|---|---|---|---|---|
| DENV1 Serotype | 326.31 (256.52 to 415.08) | 261.10 (220.90 to 308.61) | 184.85 (153.89 to 222.03) | 10.33 (8.79 to 12.14) |
| DENV2 Serotype | 815.79 (674.69 to 986.40) | 766.98 (683.66 to 860.45) | 854.59 (755.07 to 967.22) | 7.50 (7.50 to 7.50) |
| DENV3 Serotype | 203.04 (162.87 to 253.12) | 135.19 (115.70 to 157.97) | 94.69 (78.92 to 113.61) | 7.20 (6.11 to 8.48) |
| DENV4 Serotype | 102.13 (77.08 to 135.33) | 68.33 (55.80 to 83.67) | 64.43 (52.42 to 79.19) | 6.50 (6.50 to 6.50) |
An SAE is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.
| Percentage of participants | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs) | 0.0 | 0.0 | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs include pain, erythema (redness), and swelling.
| Percentage of participants | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo |
|---|---|---|---|---|
| Injection site erythema | 35.5 | 21.7 | 15.0 | 1.7 |
| Injection site pain | 34.2 | 19.7 | 13.5 | 14.8 |
| Injection site swelling | 10.0 | 5.4 | 2.4 | 2.6 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs include rash, headache, fatigue (tiredness), pyrexia (oral temperature ≥100.4 °F or 38.0 °C), myalgia (muscle pain), and arthralgia (joint pain).
| Percentage of participants | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo |
|---|---|---|---|---|
| Fatigue | 52.8 | 48.6 | 44.0 | 33.9 |
| Pyrexia | 10.8 | 7.6 | 5.7 | 0.9 |
| Arthralgia | 21.2 | 12.6 | 13.1 | 7.8 |
| Myalgia | 32.0 | 26.5 | 24.0 | 18.3 |
| Headache | 54.5 | 49.9 | 46.2 | 47.0 |
| Rash | 55.8 | 64.0 | 68.6 | 8.7 |
Collected over All-cause Mortality: Randomization up to 12 months post-vaccination; Serious Adverse Events: Vaccination up to 12 months post-vaccination; Non-Serious Adverse Events: Vaccination up to 28 Days post-vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V181 High-Potency Level | 0/231 (0%) | 8/231 (3.5%) | 200/231 (86.6%) |
| V181 Mid-Potency Level | 0/463 (0%) | 9/461 (2%) | 402/461 (87.2%) |
| V181 Low-Potency Level | 1/461 (0.2%) | 12/459 (2.6%) | 406/459 (88.5%) |
| Placebo | 0/116 (0%) | 6/115 (5.2%) | 79/115 (68.7%) |
| Event | V181 High-Potency Level | V181 Mid-Potency Level | V181 Low-Potency Level | Placebo |
|---|---|---|---|---|
| Tooth impactedGastrointestinal disorders | 0/231 | 0/461 | 0/459 | 1/115 |
| DiverticulitisInfections and infestations | 0/231 | 0/461 | 0/459 | 1/115 |
| Perineal abscessInfections and infestations | 0/231 | 0/461 | 0/459 | 1/115 |
| Scrotal abscessInfections and infestations | 0/231 | 0/461 | 0/459 | 1/115 |
| ChondromalaciaMusculoskeletal and connective tissue disorders | 0/231 | 0/461 | 0/459 | 1/115 |
| Neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/231 | 0/461 | 0/459 | 1/115 |
| Suicidal ideationPsychiatric disorders | 0/231 | 0/461 | 0/459 | 1/115 |
| Suicide attemptPsychiatric disorders | 0/231 | 0/461 | 2/459 | 0/115 |
| GastroenteritisInfections and infestations | 1/231 | 0/461 | 0/459 | 0/115 |
| Herpes simplex encephalitisInfections and infestations | 1/231 | 0/461 | 0/459 | 0/115 |
| Event | V181 High-Potency Level | V181 Mid-Potency Level | V181 Low-Potency Level | Placebo |
|---|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 129/231 | 295/461 | 315/459 | 10/115 |
| HeadacheNervous system disorders | 126/231 | 230/461 | 212/459 | 54/115 |
| FatigueGeneral disorders | 122/231 | 224/461 | 202/459 | 39/115 |
| Injection site erythemaGeneral disorders | 85/231 | 107/461 | 76/459 | 2/115 |
| Injection site painGeneral disorders | 80/231 | 91/461 | 69/459 | 18/115 |
| MyalgiaMusculoskeletal and connective tissue disorders | 74/231 | 122/461 | 110/459 | 21/115 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 49/231 | 58/461 | 60/459 | 9/115 |
| PyrexiaGeneral disorders | 25/231 | 35/461 | 26/459 | 1/115 |
| Injection site swellingGeneral disorders | 23/231 | 25/461 | 12/459 | 3/115 |
| NasopharyngitisInfections and infestations | 12/231 | 31/461 | 15/459 | 4/115 |
| Age, Continuous(Years) | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 33.8 ± 9.5 | 33.1 ± 9.8 | 33.3 ± 9.3 | 33.2 ± 9.1 | 33.3 ± 9.5 |
| Sex/Gender, Customized(Participants) | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo | Total |
|---|---|---|---|---|---|
| Female | 129 | 265 | 262 | 59 | 715 |
| Male | 102 | 198 | 198 | 57 | 555 |
| Undifferentiated | 0 | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 31 | 51 | 55 | 20 | 157 |
| Not Hispanic or Latino | 195 | 396 | 389 | 94 | 1074 |
| Unknown or Not Reported | 5 | 16 | 17 | 2 | 40 |
| Race (NIH/OMB)(Participants) | V181 High-Potency Level Group | V181 Mid-Potency Level Group | V181 Low-Potency Level Group | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 2 | 0 | 3 |
| Asian | 15 | 32 | 33 | 6 | 86 |
| Native Hawaiian or Other Pacific Islander | 1 | 3 | 2 | 0 | 6 |
| Black or African American | 5 | 12 | 14 | 9 | 40 |
| White | 207 | 406 | 400 | 100 | 1113 |
| More than one race | 2 | 10 | 10 | 1 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2022 to primary completion in Jun 2023, 8 months.
Results were first posted in May 2025, 1 year 11 months after primary completion. A results delay was requested in Mar 2024.
Of 21 industry-sponsored phase 2 interventional studies under Dengue, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's 8 months is below that.
Counting every sponsor, half of 31 studies reached it within 20 months; a quarter within 14 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: V181